LAR Octreotide

Phase 1Peptide

MMassachusetts General Hospital

LAR Octreotide is one of 26 small molecule programs targeting Carcinoid Tumor. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Carcinoid TumorActive, not recruiting

Carcinoid TumorPhase 1

Active, not recruiting

Competition

Competitive Landscape

26 competitors in Carcinoid Tumor

#DrugCompanyPhaseTrials

Estrace

Sandostatin

1 3

Cabometyx

Bristol-Myers Squibb

Phase 2

2 4

Opdivo

Bristol-Myers Squibb

Phase 2

2 5

Afinitor

Novartis

Phase 2

2 6

Cyramza

Eli Lilly

Phase 2

1 7

Sutent

Pfizer

Phase 2

1 8

Lenvima

Eisai

Phase 2

1 9

Octreotide

PEG-Intron

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Carcinoid Tumor1 trial

A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors

Withdrawn·MMassachusetts General Hospital·Phase 1·NCT03057509

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for LAR Octreotide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LAR Octreotide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LAR Octreotide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Massachusetts General Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Peptide[2]
Highest Phase: Phase 1[1]
Company: MMassachusetts General Hospital

LAR Octreotide

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Carcinoid Tumor1 trial

References

Drug Info

Quick Facts

Related News